What’s the Buzz? Cannabis is currently a multi-billion-dollar industry, with the passage of the Agriculture Improvement Act of 2018 (Farm Act) portending continued explosive growth for hemp-containing products, including CBD, in the coming years. Simultaneously, the vast majority of cannabis-derived products, including CBD, are still illegal under the Federal Food, Drug, and Cosmetic Act and in some states despite seemingly ubiquitous marketing of these products. Additionally, marijuana-containing products, although legal for medical and/or adult-use in over 30 states, remain illegal under the Controlled Substances Act, creating a confusing federal/state dynamic for the burgeoning cannabis industry.
This conference will identify uncertainties in CBD and cannabis regulation and guide attendees on how to move forward despite this uncertainty. The first day of the conference we will engage in level-setting regarding the current federal and state regulatory landscape of CBD and cannabis products. On the second day, industry experts will discuss what issues are in flux, risks and challenges for manufacturers, and what potential solutions look like for the future of regulation.
venue sponsor
This conference is designed for:
- Industry representatives interested in manufacturing and selling cannabis-derived products, such as CBD;
- Regulators that may have authority over cannabis-derived products; and
- Attorneys who practice in this space.
Conference Highlights:
- Current Federal Regulatory Landscape
- Enforcement Trends
- Existing FDA-Regulated Products Definitions and Applicability to Cannabis-Derived Products
- Agriculture Improvement Act of 2018
- Current Status of Cannabis Research and Areas for Growth
- Safety, Product Quality, Labeling, and Marketing Considerations
Keynote Address: Sharon Mayl,Senior Advisor for Policy, Office of Food Policy and Response, FDA
Sponsors
Sponsorship opportunities are available. Please let us know if you would like more information.
Planning Committee
Committee Members
Linda Bentley, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Bridget C.E. Dooling, George Washington University
William A. Garvin, Buchanan Ingersoll & Rooney PC
Aidan Hampson, National Institutes of Health, National Inst. of Drug Abuse
Jonathan Havens, Saul Ewing Arnstein & Lehr
Larry K. Houck, Hyman, Phelps & McNamara, PC
Erika Lietzan, University of Missouri – Columbia School of Law
Brian J. Malkin, Arent Fox, LLP
Patrick Moen, Privateer Holdings
Heike Newman, University of Colorado
Jessica O’Connell, Covington & Burling LLP
Christopher G. Van Gundy, Sheppard Mullin Richter & Hampton LLP